5-Amino-1MQ vs Mazdutide
5-Amino-1MQ and mazdutide differ in mechanism, trial maturity, and regulatory status. The cited studies do not establish a head-to-head efficacy ranking.
Last updated: September 28, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
5-Amino-1MQ
Dossier overview
Mazdutide
Dossier overview
What the evidence actually compares
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), not a peptide or incretin receptor agonist.
The cited 2018 experiment tested 5-Amino-1MQ in diet-induced obese mice and measured body weight and adipose endpoints. The bounded source set does not identify a human therapeutic efficacy trial for this compound. Mouse findings cannot establish human weight-loss benefit or safety. Neelakantan et al., PMID 29155147
Mazdutide is a GLP-1/glucagon receptor dual agonist. Its published GLORY-1 and GLORY-2 weight trials enrolled Chinese adults; GLORY-2 included some adults with type 2 diabetes, whereas the separate US phase 2 trial enrolled adults without it. The trials used different follow-up and analysis methods. GLORY-1 · GLORY-2 · US phase 2
Innovent reports Chinese NMPA approvals for specified adult weight-management and type 2 diabetes uses. The reviewed source is a sponsor exchange filing, not an independently retrieved Chinese label. No US FDA mazdutide approval was verified; an FDA letter identifies one US seller’s mazdutide products as unapproved new drugs.
| Evidence question | 5-Amino-1MQ | Mazdutide |
|---|---|---|
| Mechanism | 5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), not a peptide or incretin receptor agonist. | GLP-1/glucagon receptor dual agonist |
| Cited human weight evidence | No therapeutic human efficacy trial in the bounded source set | Published GLORY phase 3 studies in Chinese adults; separate US phase 2 study |
| US status in reviewed sources | No FDA approval verified | No FDA approval verified |
| China status in reviewed sources | No jurisdiction-specific conclusion from cited 5-Amino-1MQ sources | Innovent reports specified adult weight and diabetes approvals |
What cannot be inferred
The distinction is a human randomized-trial evidence gap, not a numerical source-count contest: mazdutide has published controlled weight trials in people, whereas the cited 5-Amino-1MQ result is preclinical. Different mechanisms and species leave no valid efficacy ratio or combination conclusion.
No FDA-approved 5-Amino-1MQ product was identified in the bounded regulatory review. Mazdutide’s reported Chinese approvals do not confer US approval. The source for the 5-Amino-1MQ evidence above is this primary record; regulatory claims about mazdutide are supported by the linked sponsor filing and FDA letter. No combination-use claim follows from these separate studies.
This comparison is educational research context, not medical advice or a treatment protocol.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.